|By Marketwired .||
|June 16, 2014 09:01 AM EDT||
NEWARK, CA--(Marketwired - June 16, 2014) - CymaBay Therapeutics, Inc. (OTCQB: CYMA), a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Wednesday, June 18, 2014 under the symbol "CBAY". The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol "CYMA", until the market close on Tuesday, June 17, 2014.
"Uplisting to NASDAQ is an important milestone for CymaBay. We believe that trading on NASDAQ will enhance our visibility, increase our liquidity and provide access to a broader investor base," said Harold Van Wart, President and CEO of CymaBay.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need. Arhalofenate, the Company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints through an anti-inflammatory effect while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the key debilitating symptom and the underlying cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The Company's second product candidate, MBX-8025, demonstrated favorable effects on cholesterol, triglycerides and markers of liver health in a Phase 2 clinical trial in patients with mixed dyslipidemia. MBX-8025 is currently being considered for further development in certain orphan diseases.
For additional information about CymaBay visit www.cymabay.com.
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Oct. 27, 2016 05:15 AM EDT Reads: 1,137
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Oct. 27, 2016 05:15 AM EDT Reads: 978
Oct. 27, 2016 04:45 AM EDT Reads: 435
Oct. 27, 2016 04:45 AM EDT Reads: 2,871
Oct. 27, 2016 04:30 AM EDT Reads: 464
Oct. 27, 2016 04:00 AM EDT Reads: 1,362
Oct. 27, 2016 04:00 AM EDT Reads: 762
Oct. 27, 2016 03:45 AM EDT Reads: 1,507
Oct. 27, 2016 03:45 AM EDT Reads: 1,112
Oct. 27, 2016 03:45 AM EDT Reads: 726
Oct. 27, 2016 03:45 AM EDT Reads: 4,122
Oct. 27, 2016 03:30 AM EDT Reads: 3,832
Oct. 27, 2016 03:15 AM EDT Reads: 1,863
Oct. 27, 2016 03:00 AM EDT Reads: 2,693
Oct. 27, 2016 02:45 AM EDT Reads: 1,535